



COMPANY OVERVIEW

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of LN. Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. The Company's head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The Company focuses its development efforts globally.

RECENT NEWS

[Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635\(c\)\(4\)](#)

Nov 20 2020, 5:00 PM EST

STOCK OVERVIEW

| | |
|---------------|------------------|
| Symbol | AUPH |
| Exchange | Nasdaq |
| Market Cap | 1.77b |
| Last Price | \$13.98 |
| 52-Week Range | \$6.90 - \$21.93 |

11/25/2020 04:00 PM EST

INVESTOR RELATIONS

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate
Communications and Investor Relations
IR@auriniapharma.com

MANAGEMENT TEAM

Peter Greenleaf
Chief Executive Officer, Director

Max Colao
Chief Commercial Officer

Max Donley, MBA
Executive Vice President, Internal Operations
and Strategy

Robert Huizinga, Ph.D., R.N., CNeph(C)
Executive Vice President of Research

Michael Martin
Chief Business Officer

Joe Miller
Chief Financial Officer

Stephen Robertson
Executive Vice President, General Counsel,
Corporate Secretary & Chief Compliance
Officer

Neil Solomons, M.D.
Chief Medical Officer

AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Canada

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.